Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment

Keyphrases

• Systemic Treatment 100%
• Metastatic Colorectal Cancer (mCRC) 100%
• Interferon-α (IFN-α) 100%
• Recombinant 100%
• Phase II Trial 100%
• High Dose 100%
• Leukocytes 100%
• Stopping Therapy 100%
• Confidence Interval 50%
• Primary Tumor 50%
• Resection 50%
• Tumor Mass 50%
• Median Survival 50%
• Response Rate 50%
• Weight Loss 50%
• Twice Daily 50%
• Tumor Response 50%
• Partial Response 50%
• Progressive Disease 50%
• Anorexia 50%
• Flu-like 50%
• Tumor Toxicity 50%
• Drug-related Deaths 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Phase II Trials 100%
• Metastatic Colorectal Cancer 100%
• Systemic Treatment 100%
• Alpha2 Interferon 100%
• Primary Tumor 50%
• Disease 50%
• Anorexia 50%
• Flu Like Syndrome 50%